-+ 0.00%
-+ 0.00%
-+ 0.00%

Ultragenyx Setrusumab Fails to Meet Primary Fracture Reduction Endpoint in Phase 3 Osteogenesis Imperfecta Trials

路透·12/29/2025 13:30:14

登录查看新闻详情